Auxilium Pharmaceuticals (AUXL) Announces Departure Of Chief Financial Officer - 6/3

CHESTERBROOK, Pa., June 2, 2014 -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that James E. Fickenscher, Chief Financial Officer, is leaving the Company to pursue other interests. Mr. Fickenscher will continue in his current role through August 15, 2014.

"The Board and I want to thank Jim for his nine years of service and important contributions to the evolution of Auxilium," saidAdrian Adams, Chief Executive Officer and President of Auxilium. "Over the past year, we have evolved Auxilium into a company with a leadership position in men's healthcare, and a diversified revenue stream driven by a portfolio of 12 products. We are now positioning the Company for the next phase of evolution and growth and have initiated the search for a new Chief Financial Officer. Our focus remains to execute on our visionary goals and corporate strategy and, most importantly, to deliver value to our shareholders."


Suggested Articles

Akero's FGF21 analog beat placebo at reducing liver fat in patients with nonalcoholic steatohepatitis (NASH).

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.